Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: Feasibility and efficacy

Experimental and Clinical Transplantation

Volumn 8, Issue 4, 2010, Pages 307-313

  Saab, Sammy ^a   McTigue, Michael ^a   Finn, Richard S ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; SORAFENIB; TACROLIMUS;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOS ANGELES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRIDINES; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650585002     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-156.
2. Colombo M. Risk groups and preventive strategies. In: Berr F, Bruix J, Hauss J, Wands J, Wittekind Ch, eds. Malignant Liver Tumors: Basic Concepts and Clinical Management. Dordrecht: Kluwer Academic Publishers BV and Falk Foundation; 2003:67-74.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.
4. Calne R, Yamanoi A, Oura S, Kawamura M. Liver transplantation for hepatocarcinoma. Surg Today. 1993;23(1):1-3.
5. Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology. 1990;37(2):188-193.
6. Gugenheim J, Baldini E, Casaccia M, Ouzan D, Saint-Paul MC, Mouiel J. Hepatic resection and transplantation for hepatocellular carcinoma in patients with cirrhosis [in French]. Gastroenterol Clin Biol. 1997;21(8-9):590-595.
7. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218(2):145-151.
8. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988;207(4):373-379.
9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.
10. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8(10):1982-1989.
11. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181-200.
12. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-1403.
13. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534-540.
14. Marsh JW, Dvorchik I, Subotin M, Balan V, Rakela J, Popechitelev EP, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology. 1997;26:444-450.
15. Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5(1):29-34.
16. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17(1):324-331.
17. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl. 2004;10(12):1478-1486.
18. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233(5):652-659.
19. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl. 2004;10(11):1343-1354.
20. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg. 2002;26(2):257-263.
21. Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100(12):2708-2716.
22. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol. 2003;21(23):4329-4335.
23. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2009;15(6):574-580.
24. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228(4):479-490.
25. De Carlis L, Giacomoni A, Pirotta V, Lauterio A, Slim AO, Sammartino C, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg. 2003;196(6):887-897.
26. De Carlis L, Giacomoni A, Lauterio A, Slim A, Sammartino C, Pirotta V, et al. Liver transplantation for hepatocellular cancer: should the current indication criteria be changed? Transpl Int. 2003;16(2):115-122.
27. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136(1):25-30; discussion 31.
28. Medina-Franco H, Sellers MT, Eckhoff DE, Bynon JS, Urist MM, Heslin MJ. Multimodality treatment for patients with hepatocellular carcinoma: analysis of prognostic factors in a single Western institution series. J Gastrointest Surg. 2001;5(6):638-645.
29. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg. 2002;26(2):257-263.
30. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33(5):1080-1086.
31. Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001;7(10):877-883.
32. Belli LS, Caccamo L, Mazzaferro V, Silini E, Alberti A, Melada E, et al. Milan multicenter experience in liver transplantation for hepatitis Crelated cirrhosis: report of 105 cases. Transplant Proc. 1994;26(6):3582-3584.
33. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl. 2002;8(9):736-748.
34. Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 2000;191(4):389-394.
35. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.
36. Salizzoni M, Romagnoli R, Lupo F, David E, Mirabella S, Cerutti E, et al. Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2003;76(5):844-848.
37. Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000;190(5):580-587.
38. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer. 2000;88(3):538-543.
39. Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl. 2003;9(5):513-520.
40. Lai Q, Merli M, Ginanni Corradini S, Mennini G, Gentili F, Molinaro A, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant Proc. 2009;41(4):1306-1309.
41. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int. 2007;20(9):747-753.
42. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086-1092.
43. Olthoff KM, Rosove MH, Shackleton CR, Imagawa DK, Farmer DG, Northcross P, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg. 1995;221(6):734-741; discussion 731-743. Erratum in: Ann Surg 1996;224(5):686.
44. Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE. Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc. 1993;25(1 Pt 2):1128-1129.
45. Stone MJ, Klintmalm GB, Polter D, Husberg BS, Mennel RG, Ramsay MA, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology. 1993;104(1):196-202.
46. De la Revilla NJ, Moreno JM, Rubio E, de Herreros TA, Navarrete E, Lopez MJ, et al. Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transplant Proc. 2003;35(5):1830-1831.
47. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant. 2005;5(4 Pt 1):788-794.
48. Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006;19(4):288-294.
49. Pérez Saborido B, Meneu JC, Moreno E, García I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg. 2005;190(3):383-387.
50. Oldhafer KJ, Chavan A, Frühauf NR, Flemming P, Schlitt HJ, Kubicka S, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol. 1998;29(6):953-959.
51. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226(6):688-701; discussion 701-703.
52. Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant. 2006;6(11):2644-2650.
53. Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl. 2005;11(5):494-496.
54. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235(4):533-539.
55. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17(1):324-331.
56. Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5(1):29-34.
57. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant. 2009;9(12):2851-2854.
58. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
59. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
60. Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer. 2009;115(20):4646.
61. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
62. TNM Classification of Malignant Tumours (UICC International Union Against Cancer). Sobin LH, Gospodarowicz MK, Wittekind C, eds. 5th ed. New York, Wiley-Liss; 1997:74-77.
63. Chang Liu, Qifei Wu, Bo Wang, Zheng Wu, Xuemin Liu, Xiaogang Zhang, et al. Combined pancreatoduodenectomy and orthotopic liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus: A case report. The Chinese-German Journal of Clinical Oncology. 2009;8(12):734-736.
64. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462-503.
65. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9(10):1053-1061.
66. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587-2596.